Clinical trial
Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
NCT02663297 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- June 7, 2016
- Completion date
- January 25, 2037
- Enrollment
- 18 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.